VHsquared

VHsquared’s oral domain antibodies combine the dramatic clinical impact of injectable antibody therapeutics in inflammatory bowel disease (IBD) with the benefits of oral administration, resulting in targeted activity, negligible systemic exposure and minimal immunogenicity. This approach represents a step change in the treatment of IBD and raises the possibility of treatment early in the course of the condition, reducing disease progression, improving quality of life and offering significant healthcare benefits.